Darzalex Shows Strong Efficacy in 1L Multiple Myeloma; Genmab's FVE Already Assumes Positive Results
We are maintaining Genmab’s DKK 1150 per share fair value estimate on the back of positive phase 3 Alcyone results evaluating Darzalex in frontline multiple myeloma. Our model already assumes approval in the setting. Darzalex, taken with Velcade (proteasome inhibitor), melphalan (chemotherapy), and prednisone (steroid), showed 50% reduced risk of disease progression for treatment-naïve patients compared with the same regimen sans Darzalex in an interim analysis. We believe the strong efficacy an...Genmab is a biotechnology company specializing in the creation and development of differentiated human antibody therapeutics focused on the treatment of cancer. Co.'s product pipeline includes one marketed product, Arzerra, daratumumab in late stage clinical development, four antibodies in clinical development, and over 20 in-house and partnered pre-clinical programs. Co.'s Arzerra (ofatumumab) is a human monoclonal antibody which targets an epitope on the CD20 molecule. Co.'s proprietary technologies include the DuoBody technology, which creates antibodies that can target two molecules at once, and the HexaBody technology, which allows for the creation of more potent antibodies.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.